Market Overview

UPDATE: Jefferies & Company Reiterates Buy Rating, Raises PT on Pacira Pharmaceuticals

Share:
Related PCRX
Why Is Pacira (PCRX) Down 4.5% Since the Last Earnings Report?
Leerink Presents: Your 2017 Biopharma Catalyst Tracker
Biotechs Surge As Generalists Return Amid Subsiding Trump Woes (Investor's Business Daily)

In a report published Friday, Jefferies & Company reiterated its Buy rating on Pacira Pharmaceuticals (NASDAQ: PCRX), and raised its price target from $22.00 to $24.00.

Jefferies noted, “PCRX completed a strong round of financing ($110M ‘convert' at favorable terms) removing a financing overhang – we had modeled cash needs in '13 – and provides a clear runway to profitability in '14. Q4 pre-announced Exparel sales beat estimates and the Exparel commercial metrics bode very well and support our bullish sales estimates. We raise our PT to $24 based on Exparel trends and removal of financing risk.”

Pacira Pharmaceuticals closed on Thursday at $19.43.

Latest Ratings for PCRX

DateFirmActionFromTo
Apr 2017RBC CapitalInitiates Coverage OnOutperform
Mar 2017WedbushReiteratesOutperform
Feb 2017Canaccord GenuityInitiates Coverage OnBuyBuy

View More Analyst Ratings for PCRX
View the Latest Analyst Ratings

Posted-In: Jefferies & CompanyAnalyst Color Price Target Analyst Ratings

 

Related Articles (PCRX)

View Comments and Join the Discussion!